SpyGlass Pharma Appoints Jean-Frédéric Viret, Ph.D., As CFO To Lead Finance During Late-Stage Development Of BIM-IOL System

SpyGlass Pharma™, a late-stage biopharmaceutical company, announced today the appointment of Jean-Frédéric Viret, Ph.D., as Chief Financial Officer. Dr. Viret brings more than 20 years of corporate finance experience in the life sciences sector, supporting companies through early-stage clinical development, commercialization, and post-commercial growth. At SpyGlass, he will oversee the finance and accounting functions as the company advances the Bimatoprost Drug Pad-IOL System (BIM-IOL System) toward late-stage development and potential commercialization.

Patrick Mooney, Chief Executive Officer of SpyGlass Pharma, said, “We are pleased to welcome Jean to SpyGlass Pharma as we continue to progress the clinical development of the BIM-IOL System. His extensive experience in driving successful late-stage investment while advancing clinical pipelines will be invaluable at this stage of the company’s growth.”

Dr. Viret has a strong track record of creating value for companies through the development and commercialization phases and building effective finance and accounting teams. His previous roles include Chief Financial Officer of NGM Biopharmaceuticals, Inc. and Blade Therapeutics, Inc. He also served as CFO of Coherus BioSciences, Inc. (NASDAQ: CHRS), now Coherus Oncology, a commercial-stage biopharmaceutical company, joining in 2014. In addition, Dr. Viret has held CFO positions at multiple public and privately held biopharmaceutical and diagnostics companies. He began his professional career at PwC.

Dr. Viret holds a Ph.D. in Plant Molecular Biology from Université Louis Pasteur in Strasbourg, France, a B.S. in Engineering from the Institut National Polytechnique de Lorraine, and an M.B.A. from Cornell University. He was also a visiting fellow at Harvard University and completed a postdoctoral fellowship at the Massachusetts Institute of Technology.

“I am excited to join SpyGlass at this pivotal time, following positive preliminary Phase I/II results of the BIM-IOL System in patients with open-angle glaucoma and ocular hypertension undergoing cataract surgery,” said Dr. Viret. “With the BIM-IOL System, SpyGlass is positioned to transform treatment for chronic eye conditions by improving patient adherence. I look forward to working with the leadership team to build on this strong foundation and accelerate value creation and investment across the BIM-IOL System and the company’s broader pipeline.”